The long-awaited and promising antipsychotic from Alkermes company

The new combined oral antipsychotic can be used in combination therapy.

Alkermes has approved its combined oral antipsychotic drug Lybalvi (ALKS 3831). The drug can be used in combination therapy and monotherapy in adults with schizophrenia or bipolar disorder. It can also be used as an additive to valproate or lithium preparations.

The new drug, which is a combination of the old antipsychotic olanzapine and the opioid antagonist samidorphan, is used to treat acute manic or mixed episodes. Scientists say this combination will be as effective as olanzapine and allow to avoid the key problem such as a weight gain. In clinical studies, participants who received the new drug did gain weight, but not as much as those who took olanzapine.

Source: Pharma Media